Author:
Jones N.A.,Leport M.,Holand T.,Vos T.,Morgan M.,Fink M.,Pruniaux M.-P.,Berthelier C.,O’Connor B.J.,Bertrand C.,Page C.P.
Subject
Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine
Reference30 articles.
1. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose;Nell;Am J Respir Crit Care Med,2000
2. Efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease;Leichtl;Am J Respir Crit Care Med,2002
3. CD3- and CD28-dependent induction of PDE7 required for T cell activation;Li;Science,1999
4. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness;Grewe;J Allergy Clin Immunol,1982
5. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis;Chan;J Allergy Clin Immunol,1993
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献